<DOC>
	<DOCNO>NCT00731328</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy antithymocyte globulin donor stem cell transplant help stop growth abnormal cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain abnormal cell ( graft-versus-tumor effect ) . PURPOSE : This phase II trial study well donor stem cell transplant work busulfan , fludarabine , methylprednisolone , antithymocyte globulin treat patient bone marrow failure syndrome .</brief_summary>
	<brief_title>Donor Stem Cell Transplant After Busulfan , Fludarabine , Methylprednisolone , Antithymocyte Globulin Treating Patients With Bone Marrow Failure Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate efficacy HLA-haploidentical familial donor hematopoietic stem cell transplantation reduced-intensity condition regimen comprise busulfan , fludarabine phosphate , anti-thymocyte globulin patient bone marrow failure syndrome . OUTLINE : - Reduced-intensity conditioning regimen : Patients receive busulfan IV daily day -7 -6 , fludarabine phosphate IV 30 minute day -7 -2 , anti-thymocyte globulin ( ATG ) IV 4 hour day -4 -1 , methylprednisolone IV 30 minute start 30 minute ATG day -4 -1 . - HLA-haploidentical donor hematopoietic stem cell transplantation : Patients receive donor hematopoietic stem cell via Hickman catheter 1 hour day 0 1 . - Graft-versus-host-disease prophylaxis ( GVHD ) : Patients receive cyclosporine IV 2-4 hour every 12 hour start day -1 ( cyclosporine give orally oral medication tolerate ) methotrexate IV day 2 , 4 , 7 , 12 . In absence GVHD , cyclosporine taper starting day 30 60 . After completion study treatment , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis follow bone marrow failure syndrome : Severe aplastic anemia , meet 1 follow criterion : Not responsive immunosuppressive therapy With recurrent cytopenia immunosuppressive therapy allogeneic hematopoietic cell transplantation Lowrisk myelodysplastic syndrome , include follow : Refractory anemia Refractory anemia ring sideroblast Refractory cytopenia multilineage dysplasia Paroxysmal nocturnal hemoglobinuria , meet 1 follow criterion : With thrombotic episode With severe cytopenia No willing , suitable HLAcompatible donor family donor registry Related donor HLAhaploidentical mismatch three less 6 locus Patients severe neutropenia ( &lt; 200/Î¼L ) febrile episode , feel urgent need allogeneic hematopoietic cell transplantation , eligible without search HLAmatched unrelated donor PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Bilirubin &lt; 2.0 mg/dL AST &lt; 3 time upper limit normal Creatinine &lt; 2.0 mg/dL Ejection fraction &gt; 40 % MUGA scan PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>paroxysmal nocturnal hemoglobinuria</keyword>
</DOC>